【佳學(xué)基因檢測(cè)】癌癥糖組學(xué)在 3P 醫(yī)學(xué)框架內(nèi)提供潛在的生物標(biāo)志物和治療靶點(diǎn)

做基因檢測(cè)費(fèi)用關(guān)鍵點(diǎn)

深究做了備注《Front Endocrinol (Lausanne)》在.?2022 Aug 22;13:970489.發(fā)表了一篇題目為《癌癥糖組學(xué)在 3P 醫(yī)學(xué)框架內(nèi)提供潛在的生物標(biāo)志物和治療靶點(diǎn)》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Yuna Guo,?Wenshuang Jia,?Jingru Yang,?Xianquan Zhan等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

3P醫(yī)學(xué),癌癥生物標(biāo)志物,熒光成像,糖基化,免疫化學(xué)方法,免疫療法,凝集素識(shí)別,質(zhì)譜

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

糖基化是蛋白質(zhì)中賊重要的翻譯后修飾 (PTM) 之一，是自然界中賊豐富多樣的生物聚合物。聚糖參與癌癥發(fā)生和發(fā)展的多個(gè)生物學(xué)過(guò)程，包括細(xì)胞-細(xì)胞相互作用、細(xì)胞-細(xì)胞外基質(zhì)相互作用、腫瘤侵襲和轉(zhuǎn)移、腫瘤血管生成和免疫調(diào)節(jié)。作為一種重要的生物標(biāo)志物，腫瘤相關(guān)的糖基化變化已被廣泛研究。本文回顧了基于糖基化的生物標(biāo)志物研究的賊新進(jìn)展，這對(duì)于癌癥診斷和預(yù)后評(píng)估很有用。已發(fā)現(xiàn)截短的 O-聚糖、唾液酸化、巖藻糖基化和復(fù)雜的分支結(jié)構(gòu)是惡性腫瘤中賊常見的結(jié)構(gòu)模式。近年來(lái)，免疫化學(xué)方法、基于凝集素識(shí)別的方法、質(zhì)譜（MS）相關(guān)方法和基于熒光成像的原位方法極大地促進(jìn)了糖組學(xué)和糖蛋白生物標(biāo)志物在各種癌癥中的發(fā)現(xiàn)和應(yīng)用潛力。特別是，基于 MS 的蛋白質(zhì)組學(xué)極大地促進(jìn)了細(xì)胞外糖蛋白的綜合研究，增加了我們對(duì)它們?cè)谡{(diào)節(jié)細(xì)胞活動(dòng)中的關(guān)鍵作用的理解。預(yù)測(cè)、預(yù)防和個(gè)體化醫(yī)療（PPPM；3P醫(yī)學(xué)）是針對(duì)不同患者進(jìn)行早期預(yù)測(cè)、預(yù)防和個(gè)體化治療的有效途徑，被譽(yù)為21世紀(jì)醫(yī)學(xué)發(fā)展的新方向，代表著先進(jìn)目標(biāo)和賊高境界。醫(yī)學(xué)發(fā)展階段。已發(fā)現(xiàn)糖基化具有新的診斷、預(yù)后甚至治療潛力。糖基化分析和生物學(xué)利用的目的是對(duì)醫(yī)療保健和醫(yī)療實(shí)踐進(jìn)行根本性的改變，從而引領(lǐng)醫(yī)學(xué)研究和實(shí)踐進(jìn)入3P醫(yī)學(xué)的新時(shí)代。關(guān)鍵詞：3P醫(yī)學(xué)；癌癥生物標(biāo)志物；熒光成像；糖基化；免疫化學(xué)方法；免疫療法；凝集素識(shí)別；質(zhì)譜。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Glycosylation is one of the most important post-translational modifications (PTMs) in a protein, and is the most abundant and diverse biopolymer in nature. Glycans are involved in multiple biological processes of cancer initiation and progression, including cell-cell interactions, cell-extracellular matrix interactions, tumor invasion and metastasis, tumor angiogenesis, and immune regulation. As an important biomarker, tumor-associated glycosylation changes have been extensively studied. This article reviews recent advances in glycosylation-based biomarker research, which is useful for cancer diagnosis and prognostic assessment. Truncated?O-glycans, sialylation, fucosylation, and complex branched structures have been found to be the most common structural patterns in malignant tumors. In recent years, immunochemical methods, lectin recognition-based methods, mass spectrometry (MS)-related methods, and fluorescence imaging-based?in situ?methods have greatly promoted the discovery and application potentials of glycomic and glycoprotein biomarkers in various cancers. In particular, MS-based proteomics has significantly facilitated the comprehensive research of extracellular glycoproteins, increasing our understanding of their critical roles in regulating cellular activities. Predictive, preventive and personalized medicine (PPPM; 3P medicine) is an effective approach of early prediction, prevention and personalized treatment for different patients, and it is known as the new direction of medical development in the 21st century and represents the ultimate goal and highest stage of medical development. Glycosylation has been revealed to have new diagnostic, prognostic, and even therapeutic potentials. The purpose of glycosylation analysis and utilization of biology is to make a fundamental change in health care and medical practice, so as to lead medical research and practice into a new era of 3P medicine.Keywords:?3P medicine; cancer biomarker; fluorescence imaging; glycosylation; immunochemical method; immunotherapy; lectin recognition; mass spectrometry.